[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633860":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":72,"collaborators":12,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":12,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":12,"enrollmentInfo":83,"targetDuration":12,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":39,"whyStopped":12,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Efferon JSC","INDUSTRY",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Baseline therapy","NO_INTERVENTION","Patients will be treated according to the standard protocol for cardiac surgery with cardiopulmonary bypass without hemoadsorption.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Basic therapy + Efferon LPS","EXPERIMENTAL","Patients will be treated according to the standard protocol for cardiac surgery with cardiopulmonary bypass and will receive hemoadsorption with Efferon LPS.",[18],"Device: Efferon LPS",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DEVICE","Efferon LPS","Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.\n\nEfferon LPS hemoadsorption will be performed twice: first during cardiopulmonary bypass (CPB) at the time of cardiac surgery, with the duration determined by the CPB time, and second within 24 hours postoperatively, for a minimum duration of 6 hours.",[14],[26],{"name":27,"affiliation":28,"role":29},"Yuri Polushin, PhD, MD","Pavlov First Saint Petersburg State Medical University","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":12,"email":35},"Alexandr Shelehov-Kravchenko, PhD, MD","CONTACT","+79636564765","ais@efferon.ru",[37,53,65],{"facility":38,"status":39,"city":40,"state":12,"zip":12,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Regional State Budgetary Healthcare Institution \"Altai Regional Cardiological Dispensary\"","RECRUITING","Barnaul","Russia","RU",{"type":44,"coordinates":45},"Point",[46,47],83.72786,53.36199,{"lat":47,"lon":46},[50],{"name":51,"role":33,"phone":12,"phoneExt":12,"email":52},"Alexander Efremushkin, PhD, MD","zavoar1@akkd.ru",{"facility":54,"status":39,"city":55,"state":12,"zip":12,"country":41,"countryCode":42,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Almazov National Medical Research Centre","Saint Petersburg",{"type":44,"coordinates":57},[58,59],30.31413,59.93863,{"lat":59,"lon":58},[62],{"name":63,"role":33,"phone":12,"phoneExt":12,"email":64},"Andrey Bautin, PhD, MD","bautin_ae@almazovcentre.ru",{"facility":28,"status":39,"city":55,"state":12,"zip":12,"country":41,"countryCode":42,"cosmosGeoPoint":66,"geoPoint":68,"contacts":69},{"type":44,"coordinates":67},[58,59],{"lat":59,"lon":58},[70],{"name":27,"role":33,"phone":12,"phoneExt":12,"email":71},"polushin1@gmail.com",{"type":73,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100633860","efferon-lps-hemoadsorption-in-cardiac-surgery-patients-100633860",false,"NCT07532174","Efferon LPS Hemoadsorption in Cardiac Surgery Patients","Intraoperative and Early Postoperative Use of Lipopolysaccharide Adsorption (Efferon LPS) in Cardiac Surgery Patients to Reduce the Incidence of Multiple Organ Dysfunction Syndrome in the Postoperative Period","Inclusion Criteria:\n\n* Adult patients undergoing elective or emergency cardiac surgery with the use of cardiopulmonary bypass (CPB).\n* EuroSCORE II ≥6%\n\nExclusion Criteria:\n\n* Procalcitonin ≥2 ng\u002FmL\n* Severe chronic liver disease, defined as Child-Pugh class C (\\>10 points) or clinically manifest hepatic failure\n* Dialysis-dependent chronic kidney disease (CKD)\n* Ongoing immunosuppressive therapy, including corticosteroids or cytotoxic agents, excluding standard perioperative medications\n* Any other clinical condition that, in the investigator's opinion, would preclude the patient's participation in the study","ALL","18 Years",{"count":84,"type":85},60,"ESTIMATED","INTERVENTIONAL",[88],"NA","This randomized controlled study aims to evaluate the efficacy and safety of intraoperative and early postoperative hemoadsorption using the Efferon® LPS device in patients undergoing cardiac surgery with cardiopulmonary bypass in reducing the incidence and severity of multiple organ dysfunction syndrome (MODS) in the postoperative period. Each patient in the treatment group will undergo two hemoadsorption sessions: first during cardiopulmonary bypass (CPB) at the time of cardiac surgery, with the duration determined by the CPB time, and second within 24 hours postoperatively, for a minimum duration of 6 hours.",[91,92],"Cardiac Disease","Multiple Organ Dysfunction Syndrome",[94,95,96,97],"Hemoadsorption","Hemoperfusion","Extracorporeal therapy","LPS adsorption","2026-04-09",{"date":100,"type":101},"2026-04-15","ACTUAL",{"date":100,"type":85},{"date":104,"type":85},"2028-01-31",{"name":5,"class":6},3]